3.4.21.B42: hippostasin
This is an abbreviated version!
For detailed information about hippostasin, go to the full flat file.
Word Map on EC 3.4.21.B42
-
3.4.21.B42
-
kallikreins
-
klk8
-
prostate-specific
-
medicine
-
soman
-
diagnostics
-
immunofluorometric
- 3.4.21.B42
- kallikreins
- klk8
-
prostate-specific
- medicine
- soman
- diagnostics
-
immunofluorometric
Reaction
proteolytic cleavage of polypeptides, preferential cleavage site: Arg- =
Synonyms
brain-type KLK11, GK-11, glandular kallikrein K11, hippostatin, hK11, human kallikrein 11, kallikrein 11, kallikrein-like protease, kallikrein-related peptidase 11, KLK11, prostate-type KLK11, S01.257, tissue kallikrein, tissue kallikrein 11, TLSP
ECTree
Advanced search results
Application
Application on EC 3.4.21.B42 - hippostasin
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
diagnostics
medicine
the measurement of kallikrein-related peptidase 11, KLK11, might be a useful diagnostic and prognostic test for non-small cell lung cancer patients. Patients with a high enzyme activity have a longer longer overall survival and progression free survival
diagnostics
elevated tumor tissue protein expression levels of kallikrein-related peptidases KLK10 and KLK11 are associated with a favorable prognosis in advanced high-grade serous ovarian cancer patients
-
KLK11 mRNA may serve as a marker to discriminate between benign prostatic hyperplasia and prostate cancer
medicine
overexpression of human kallikrein 11 is associated with poor prognosis in patients with low rectal carcinoma
medicine
-
the down-regulation of KLK11 gene in advanced and more aggressive tumors opens the feasibility of being used as biomarker distinguishing the tumor aggressiveness and prognostic indicators for human prostate cancer
medicine
-
negative kallikrein 11 expression is associated with nearly 5fold increased risk of distant metastasis after curative gastrectomy in gastric cancer patients. Kallikrein 11 expression is a significant independent prognostic factor for disease-free survival and overall survival in gastric cancer patients